Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • MORE +
    • Contact Us
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Politics & Policy
July 24, 2020 04:33 PM

Trump issues drug pricing executive orders on 340B, outpatient drug pay

Rachel Cohrs and Michael Brady
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Modern Healthcare Illustration / Getty Images

    President Donald Trump on Friday announced four executive orders to advance policies forcing community health centers that receive 340B drug discounts to cut patients' costs for Epi-Pens and insulin, tying Medicare payment for outpatient drugs to international prices, passing drugmaker rebates to patients and allowing personal drug importation.

    The executive orders come as Trump's poll numbers are suffering and the GOP is scrambling to solidify its healthcare messaging ahead of the 2020 election. However, the policies still have to advance through the regulatory process and are unlikely to be implemented before the election, if ever.

    "For now, these policies should be taken for what they are: campaign fodder. Whether there will be any interest in following through with them should the president be reelected remains to be seen," American Action Forum director of healthcare policy Chris Holt wrote Friday.

    340B discounts

    The administration's plan to lower patient's out-of-pocket costs for Epi-Pens and insulin would force federal community health centers to pass on their 340B drug discounts to patients, Trump said during a press conference.

    HHS' rulemaking power over the 340B program is very limited, said Helen Pfister, partner at Manatt Health. The Trump administration plans to strong-arm community health centers by denying them future grants unless they pass on their discounts to patients.

    According to the executive order, federally qualified community health centers would have to give their discounts to patients with high cost-sharing for insulin or Epi-Pens, a high unmet deductible or who are uninsured.

    The move wouldn't make much of a dent in drug prices because it wouldn't affect most providers or patients.

    The 340B program allows safety-net providers, some disease-specific programs, and publicly owned hospitals with sizable disproportionate-share populations to buy outpatient drugs at steeply reduced prices from manufacturers. Congress created the program in 1992 to fix the newly created Medicaid drug rebate program, which accidentally led pharmaceutical companies to stop offering discounts to safety-net providers.

    But the program has expanded dramatically in recent years, drawing the ire of drugmakers and some public officials. HHS' Health Resources and Services Administration found drugs purchased under the program totaled about $16 billion or about 3.6% of all drugs in 2016. In addition, the Government Accountability Office has cited numerous oversight issues, which could lead to duplicate discounts being paid to providers.

    The Trump administration and 340B hospitals have also been entangled in an ongoing battle over the administration's attempts to cut 340B payments to hospitals.

    International reference pricing

    The Trump administration also threatened to advance a proposal that would tie Medicare outpatient drug payments to the lowest international price in a market basket of developed countries if drugmakers don't propose an alternative by Aug. 24.

    Ipsita Smolinski, managing director of the consulting firm Capitol Street, said she wasn't sure what preferable alternative drugmakers could put forward.
    "I don't think drugmakers can collude with each other to lower their prices by 40% overnight," Smolinski said.

    HHS said Friday that the policy would limit Medicare Part B payments to the lowest price charged in "any economically comparable" developed country, which is different than a prior proposal that would have tied payments to an average international price.

    Abe Sutton, a former advisor to HHS and the White House Domestic Policy Council, said both an average price and a lowest price guarantee would have a similar overall effect, likely making other developed countries pay more for drugs.
    Drugmakers hate the proposal and argue it would harm their capacity to develop new drugs — an argument that industry allies had expected to be more poignant as the nation looks to drugmakers to develop a COVID-19 vaccine during a pandemic.

    "The research-based biopharmaceutical industry has been working around the clock to develop therapeutics and vaccines to treat and prevent COVID-19," said Pharmaceutical Research and Manufacturers of America President and CEO Stephen Ubl. "The administration's proposal today is a reckless distraction that impedes our ability to respond to the current pandemic – and those we could face in the future."

    The international reference pricing policy could also change the way doctors are paid for administering outpatient drugs, and create a middleman between providers and drugmakers.

    HHS' initial draft of the proposal would change physician payment to a set price for administering a drug, instead of a payment as a percentage of a drug's average sales price. HHS said its goal was to hold physicians' revenue harmless in the new model.

    Rebate rule

    The White House has also decided to revive a proposal to pass drugmaker rebates to patients' cost-sharing in Medicare Part D. However, the executive order includes a provision that could prove to be a poison pill.

    The White House last summer pulled the regulation after it was determined to be one of the most expensive ever promulgated — the Congressional Budget Office estimated the price tag at at $177 billion from 2020-2029. It was also estimated to raise Medicare beneficiaries' premiums.

    But the executive order says the rebate rule can't be advanced unless the HHS secretary gave public confirmation that the rule would not raise premiums, taxpayer spending, or out-of-pocket costs.

    Drugmakers love the idea, as the rebates they pay to plans to secure favorable formulary placement would be reflected in patients' copays. Insurance plans and pharmacy benefit managers detest the plan and have fiercely lobbied against it.

    The insurer-backed Campaign for Sustainable Rx Pricing claimed the policy's inclusion was a capitulation to drugmakers.

    "The reboot of the Rebate Rule would hand Big Pharma a massive bailout paid for on the backs of American seniors and taxpayers," CSRxP Executive Director Lauren Aronson said.

    Importation

    The Trump administration is also exploring allowing some personal importation of prescription drugs, HHS Secretary Alex Azar said.

    "Individuals could get their drugs imported from other countries that the FDA would set up a system that would allow the safe importation from systems that have comparable regulatory regimes where FDA would find that to be safe," Azar told reporters Friday.

    The administration's current plans would only allow states and drugmakers to import some prescription drugs. The Food and Drug Administration issued a proposed rule in December that would allow states to pursue pilot programs to import drugs from Canada and a draft guidance that would allow drugmakers to import their own products and sell them under different drug codes.

    Skeptics have voiced concerns about the safety of the plan, and whether Canada's drug supply could handle funneling drugs to the U.S.

    Investors and analysts aren't expecting immediate bottom-line impacts from the orders, as many of the initiatives have to go through lengthy rulemaking processes.
    "No matter what came out today, it's tough to get to a world where they are enacted and hitting bottom lines," said Height Capital Markets senior analyst Hunter Hammond.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Copy of congressional_266dpi_CORRECT_i.jpg
    House passes $1.7T spending bill
    congress, capitol building, legislation
    Senate passes $1.7T bill to fund government
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • MORE +
      • Contact Us
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing